Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Plandai Biotechnology's earnings before interest and taxes (EBIT) for the
six
months ended in Jun. 2023 was $-19.77 Mil.
Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.77 Mil.
EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.
Plandai Biotechnology's annualizedROC % for the quarter that ended in Jun. 2023 was -120.07%.
Plandai Biotechnology's annualizedROC (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was %.
EBIT is also linked to Joel Greenblatt's definition of earnings yield.
Plandai Biotechnology's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2023 was -4,403.79%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Business Services subindustry, Plandai Biotechnology's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Plandai Biotechnology EV-to-EBIT vs Business Services Industry
For the Business Services industry and Industrials sector, Plandai Biotechnology's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Plandai Biotechnology's EV-to-EBIT falls into.
EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.
For stock reported annually, GuruFocus uses latest annual data as the TTM data. EBIT for the trailing twelve months (TTM) ended in Jun. 2023 was $-19.77 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Plandai Biotechnology (PLPL) has a EBIT of $-19.77 Mil as of Jun. 2023. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Plandai Biotechnology.
Is Plandai Biotechnology's EBIT too high?
Plandai Biotechnology's current EBIT is $-19.77 Mil.
How does Plandai Biotechnology's EBIT compare to CRGH and TCRI?
Plandai Biotechnology's EBIT of $-19.77 Mil can be compared against companies in the Business Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Business Services company?
A good EBIT depends on the Business Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Plandai Biotechnology. Plandai Biotechnology's current EBIT is $-19.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Plandai Biotechnology stock overvalued right now?
Plandai Biotechnology (PLPL) has a current EBIT of $-19.77 Mil. The current EBIT is $-19.77 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Plandai Biotechnology (PLPL), the current EBIT is $-19.77 Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PLPL has been successfully added to your 
